Table 4:
Linear models for change in As metabolite proportions over 12 weeks, by baseline choline strata. a
| Low strata (≤ median) | High strata (> median) | Test for difference between strata b | |||||
|---|---|---|---|---|---|---|---|
| Change (week 12 - week 0) | Treatment vs. placebo | B (95% CI) | P | B (95% CI) | P | P | FDR |
| ln(%InAs) c | 400FA | −0.12 (−0.24, 0.01) | 0.078 | −0.12 (−0.24, 0.00) | 0.048 | 0.96 | 0.96 |
| 800FA | −0.15 (−0.27, −0.03) | 0.017 | −0.23 (−0.34, −0.12) | <0.001 | 0.34 | 0.69 | |
| Creatine | 0.05 (−0.09, 0.19) | 0.47 | −0.11 (−0.22, 0.00) | 0.053 | 0.077 | 0.31 | |
| Creatine+400FA | −0.12 (−0.30, 0.06) | 0.19 | −0.14 (−0.25, −0.03) | 0.012 | 0.86 | 0.96 | |
| %MMAs d | 400FA | −3.00 (−4.09, −1.91) | <0.001 | −1.25 (−2.25, −0.25) | 0.014 | 0.020 | 0.078 |
| 800FA | −3.23 (−4.34, −2.12) | <0.001 | −1.76 (−2.72, −0.80) | <0.001 | 0.049 | 0.097 | |
| Creatine | −1.47 (−2.88, −0.07) | 0.040 | 0.05 (−1.09, 1.18) | 0.94 | 0.098 | 0.11 | |
| Creatine+400FA | −2.91 (−4.11, −1.72) | <0.001 | −1.55 (−2.72, −0.38) | 0.010 | 0.11 | 0.11 | |
| %DMAs e | 400FA | 4.53 (2.03, 7.04) | <0.001 | 2.71 (0.71, 4.72) | 0.008 | 0.27 | 0.93 |
| 800FA | 5.54 (3.21, 7.88) | <0.001 | 4.58 (2.72, 6.44) | <0.001 | 0.52 | 0.93 | |
| Creatine | 0.93 (−1.98, 3.83) | 0.53 | 1.53 (−0.41, 3.47) | 0.121 | 0.73 | 0.93 | |
| Creatine+400FA | 3.10 (−0.24, 6.44) | 0.069 | 3.27 (1.35, 5.19) | 0.001 | 0.93 | 0.93 | |
InAs = inorganic arsenic; MMAs = monomethyl−arsenical species; DMAs = dimethyl−arsenical species (DMAs
PMI = primary methylation index measured in urine. SMI = secondary methylation index measured in urine.
FDR = false discovery rate.
a.
Placebo used as reference group. Baseline choline median = 11.42 nmol/mL.
b.
Wald test for difference between low and high strata.
c.
Adjusted for baseline ln(%InAs).
d.
Adjusted for baseline %MMAs.
e.
Adjusted for baseline %DMAs.